Showing 121-140 of 498 for: Cochrane Systematic Reviews > Neurologic 
- Corticosteroids for the long‐term treatment in multiple sclerosis
Cochrane Systematic Reviews, 23-Jan-2008
Short term high dose corticosteroid treatment improves symptoms and short term disability after an acute exacerbation of multiple sclerosis (MS) but it is unknown whether its long-term use can reduce the accumulation of disability.
- Corticosteroids for the treatment of Duchenne muscular dystrophy
Cochrane Systematic Reviews, 5-May-2016
Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy of childhood. Untreated, this incurable disease, which has an X-linked recessive inheritance, is characterised by muscle wasting and loss of walking ability, leading to complete wheel
- Corticosteroids for treating nerve damage in leprosy
Cochrane Systematic Reviews, 23-May-2016
Leprosy causes nerve damage that can result in nerve function impairment and disability. Corticosteroids are commonly used for treating nerve damage, although their long-term effect is uncertain. This is an update of a review first published in 2007, and
- Corticosteroids for treating optic neuritis
Cochrane Systematic Reviews, 14-Aug-2015
Optic neuritis is an inflammatory disease of the optic nerve. It usually presents with an abrupt loss of vision and recovery of vision is almost never complete. It occurs more commonly in women than in men. Closely linked in pathogenesis, optic neuritis m
- Corticosteroids including ACTH for childhood epilepsy other than epileptic spasms
Cochrane Systematic Reviews, 18-Jun-2015
This is an updated version of the original Cochrane review published in Issue 1, 2007.
- Corticosteroids or ACTH for acute exacerbations in multiple sclerosis
Cochrane Systematic Reviews, 12-Nov-2013
Corticosteroids are commonly used to improve the rate of recovery from acute exacerbation in multiple sclerosis (MS) patients. However, it is unclear just how effective these agents are and which is the best treatment schedule (type of drug, dose, frequen
- Cranial irradiation for preventing brain metastases of small cell lung cancer in patients in complete remission
Cochrane Systematic Reviews, 6-Feb-2018
Prophylactic cranial irradiation halves the rate of brain metastases in patients with small cell lung cancer. Individual randomized trials conducted on patients in complete remission were unable to clarify whether this treatment improves survival.
- Creatine for amyotrophic lateral sclerosis/motor neuron disease
Cochrane Systematic Reviews, 14-Nov-2012
Creatine, a naturally-occurring nitrogenous organic acid involved in adenosine triphosphate (ATP) production, has been shown to increase survival in mouse models of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND). Results fro
- Creatine for treating muscle disorders
Cochrane Systematic Reviews, 5-Jun-2013
Progressive muscle weakness is a main symptom of most hereditary and acquired muscle diseases. Creatine improves muscle performance in healthy individuals. This is an update of our 2007 Cochrane review that evaluated creatine treatment in muscle disorders
- Cyclophosphamide for multiple sclerosis
Cochrane Systematic Reviews, 24-Jan-2007
Multiple sclerosis is a presumed cell-mediated autoimmune disease of the central nervous system. Cyclophosphamide (CFX) is a cytotoxic and immunosuppressive agent, used in systemic autoimmune diseases. Controversial results have been reported on its effic
- Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly
Cochrane Systematic Reviews, 27-Apr-2008
CDP-choline (cytidine 5'-diphosphocholine) is a precursor essential for the synthesis of phosphatidylcholine, one of the cell membrane components that is degraded during cerebral ischaemia to free fatty acids and free radicals. Animal studies suggest that
- Daclizumab for relapsing remitting multiple sclerosis
Cochrane Systematic Reviews, 17-Dec-2013
Monoclonal antibodies such as daclizumab could be a possible alternative immunotherapy to interferon beta treatment in people with multiple sclerosis (MS). It blocks the interleukin-2 receptor alpha subunit (CD25), and seems to be beneficial to patients w
- D-cycloserine for Alzheimer's disease
Cochrane Systematic Reviews, 5-May-2008
Evidence supports a role for NMDA receptors in learning and memory. These can be modulated by the antibiotic D-cycloserine in such a way that the effect of the excitatory transmitter substance glutamate is enhanced. A study on healthy subjects pretreated
- Decompressive craniectomy for the treatment of high intracranial pressure in closed traumatic brain injury
Cochrane Systematic Reviews, 31-Dec-2019
High intracranial pressure (ICP) is the most frequent cause of death and disability after severe traumatic brain injury (TBI). It is usually treated with general maneuvers (normothermia, sedation, etc.) and a set of first-line therapeutic measures (modera
- Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people
Cochrane Systematic Reviews, 18-Dec-2008
In view of the theoretical possibility of beneficial effects of DHEA retarding age-associated deterioration in cognitive function, we have reviewed studies in this area.
- Diazepam for treating tetanus
Cochrane Systematic Reviews, 26-Jan-2004
Clinical management of the muscle spasms and rigidity of tetanus poses a difficult therapeutic problem to physicians everywhere, especially in resource poor countries. There are wide variations in therapeutic regimens commonly used in clinical practice du
- Diclofenac for acute pain in children
Cochrane Systematic Reviews, 10-Jun-2019
Diclofenac is commonly used for acute pain in children, but is not licensed for this indication in all age groups.
- Dietary interventions for multiple sclerosis‐related outcomes
Cochrane Systematic Reviews, 19-May-2020
Multiple sclerosis (MS) is a common demyelinating disease of the central nervous system. Although the exact pathogenesis remains unknown, the leading theory is that it results from immune system dysregulation. Approved disease-modifying therapy appears to
- Dipyrone for acute primary headaches
Cochrane Systematic Reviews, 10-Jun-2019
Dipyrone is used to treat headaches in many countries, but is not available in others (particularly the USA and UK) because of its association with potentially life-threatening blood dyscrasias such as agranulocytosis.
- Donepezil for dementia due to Alzheimer's disease
Cochrane Systematic Reviews, 18-Jun-2018
Alzheimer's disease is the most common cause of dementia in older people. One approach to symptomatic treatment of Alzheimer's disease is to enhance cholinergic neurotransmission in the brain by blocking the action of the enzyme responsible for the breakd
